Eli Lilly and Company: Depressive Disorder, Major trials

The registry lists 58 Depressive Disorder, Major studies with Eli Lilly and Company as lead sponsor. 3 are open to participants now and 42 have results posted.

Phase 1 17Phase 2 5Phase 3 22Phase 4 13No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Brenipatide in Participants With Major Depressive DisorderNot yet recruitingNCT07928245Phase 2
• A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive DisorderRecruitingNCT07775300Phase 3
• A Study of Brenipatide in Adult Participants With Major Depressive DisorderRecruitingNCT07412756Phase 3
• A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term DosingCompletedNCT01808651Phase 3Results posted
• A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term DosingCompletedNCT01808612Phase 3Results posted
• A Study to Evaluate the Effect of Clarithromycin on LY2216684CompletedNCT01460407Phase 1Results posted
• A Study to Evaluate the Effect of Genotype on LY2216684CompletedNCT01460381Phase 1Results posted
• A Study to Evaluate the Effect of Food on LY2216684CompletedNCT01389765Phase 1Results posted
• A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy SubjectsCompletedNCT01389752Phase 1Results posted
• A Study of LY2216684 in Healthy ParticipantsCompletedNCT01380691Phase 1Results posted
• A Study of LY2216684 in Healthy FemalesCompletedNCT01373931Phase 1Results posted
• A Study of LY2216684 in Participants With Major Depression DisorderCompletedNCT01370499Phase 3Results posted
• A Study in Prevention of Re-emergence of Depression SymptomsCompletedNCT01299272Phase 3Results posted
• A Study of the Effect of LY2216684 on LorazepamCompletedNCT01275144Phase 1Results posted
• A Study of LY2216684 and Digoxin in Healthy SubjectsCompletedNCT01266590Phase 1Results posted
• A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake InhibitorsCompletedNCT01263223Phase 1Results posted
• A Study of LY2216684 in Healthy Participants Receiving Albuterol or PropanololCompletedNCT01263197Phase 1Results posted
• A Study of LY2216684 and Warfarin in Healthy SubjectsCompletedNCT01263119Phase 1Results posted
• A Study of LY2216684 and Theophylline in Healthy SubjectsCompletedNCT01263106Phase 1Results posted
• A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of ClopidogrelCompletedNCT01263093Phase 1Results posted
• A Pharmacokinetic Study of the Coadministration of LY2216684 With SertralineCompletedNCT01250873Phase 1Results posted
• A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.CompletedNCT01243957Phase 1Results posted
• A Study of LY2216684 in Participants With Impaired Hepatic FunctionCompletedNCT01241435Phase 1Results posted
• A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) TreatmentCompletedNCT01187407Phase 3Results posted
• A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake InhibitorCompletedNCT01185340Phase 3Results posted
• A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive DisorderCompletedNCT01173601Phase 3Results posted
• A Safety Study in Participants With Major Depressive DisorderCompletedNCT01155661Phase 3Results posted
• A Study in Depression and Associated Painful Physical SymptomsCompletedNCT01070329Phase 4Results posted
• A Study of the Neurobiology of DepressionCompletedNCT01051466Phase 4Results posted
• A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful SymptomsCompletedNCT01000805Phase 4Results posted
• A Study of Patients With Major Depressive Disorder and Residual ApathyCompletedNCT00985504Phase 4Results posted
• A Duloxetine Dosing Strategy Study in Korean Patients With Major Depressive DisorderCompletedNCT00960986Phase 4Results posted
• A Study in the Treatment of Children and Adolescents With Major Depressive DisorderCompletedNCT00849901Phase 3Results posted
• A Study in the Treatment of Children and Adolescents With Major Depressive DisorderCompletedNCT00849693Phase 3Results posted
• A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive DisorderCompletedNCT00840034Phase 2Results posted
• Early Versus Delayed Switch in Medication in Patients With Major Depressive DisorderCompletedNCT00810069Phase 4Results posted
• A Study in Adult Patients With Major Depressive DisorderCompletedNCT00795821Phase 2/3Results posted
• Switching to Duloxetine in Patients With DepressionCompletedNCT00696774Phase 4Results posted
• A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) PatientsCompletedNCT00536471Phase 4Results posted
• Open-Label Study of Duloxetine in the Treatment of Children and Adolescents With Major Depressive DisorderCompletedNCT00529789Phase 2Results posted
• Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's DiseaseCompletedNCT00437125Phase 4Results posted
• A Study Evaluating Duloxetine in Patients Hospitalized for Severe DepressionCompletedNCT00422162Phase 4Results posted
• A Study for Participants With Major DepressionCompletedNCT00420004Phase 2Results posted
• A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly PatientsCompletedNCT00406848Phase 4Results posted
• Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive DisorderCompletedNCT00105989Phase 3Results posted
• Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 MonthsCompletedNCT00561509
• Duloxetine Versus Paroxetine for Major DepressionCompletedNCT00489775Phase 3
• Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)CompletedNCT00479726Phase 4
• Evaluation of the Effects of Duloxetine on NorepinephrineCompletedNCT00414323Phase 1
• Switching to Duloxetine From Other AntidepressantsCompletedNCT00191932Phase 4
• A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and PainCompletedNCT00191919Phase 3
• Duloxetine in the Treatment of Melancholic DepressionCompletedNCT00191685Phase 3
• Open-Label Duloxetine Extension Phase in Patients Who Have Completed Previous Duloxetine TrialsCompletedNCT00191594Phase 3
• Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical TrialApproved for marketingNCT00071708
• Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major DepressionCompletedNCT00042575Phase 3
• Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major DepressionCompletedNCT00042562Phase 3
• Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive DisorderCompletedNCT00036309Phase 3
• The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant DepressionCompletedNCT00035321Phase 3